[{"id":"c15a52de-3419-47f0-9b51-09f2e18386cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05964985","created_at":"2023-07-31T17:08:51.096Z","updated_at":"2024-07-02T16:35:41.679Z","phase":"","brief_title":"Effect of Quadratus Lumborum Block With Compound Lidocaine and Esketamine on Pain After Colorectal Surgery","source_id_and_acronym":"NCT05964985","lead_sponsor":"Tianjin Medical University General Hospital","biomarkers":" CCL2 • IL18 • IL17A • IL23A • CXCL1","pipe":"","alterations":" ","tags":["CCL2 • IL18 • IL17A • IL23A • CXCL1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 08/06/2023","start_date":" 08/06/2023","primary_txt":" Primary completion: 01/15/2024","primary_completion_date":" 01/15/2024","study_txt":" Completion: 02/15/2024","study_completion_date":" 02/15/2024","last_update_posted":"2023-07-28"},{"id":"1d76bd59-1106-4b42-9f95-8ec48f34176c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05366569","created_at":"2022-05-09T11:56:31.025Z","updated_at":"2024-07-02T16:35:42.352Z","phase":"","brief_title":"Bio-CAR-T BS Study","source_id_and_acronym":"NCT05366569","lead_sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","biomarkers":" IL6 • IL2 • IL10 • FAP • IL17A • IL23A • IL22 • GFAP","pipe":"","alterations":" ","tags":["IL6 • IL2 • IL10 • FAP • IL17A • IL23A • IL22 • GFAP"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 04/26/2022","start_date":" 04/26/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2023-07-21"},{"id":"3a1a5254-3234-4524-b5ba-287fea6ff089","acronym":"","url":"https://clinicaltrials.gov/study/NCT03823651","created_at":"2021-03-02T16:53:11.206Z","updated_at":"2024-07-02T16:35:58.847Z","phase":"","brief_title":"A Research Program Targeting Pre- and Peri-transplant Optimization Program (R-PPOP)","source_id_and_acronym":"NCT03823651","lead_sponsor":"Duke University","biomarkers":" IL6 • FLT1 • IL2 • IL10 • VEGFC • FGF • IL17A • IL23A • IL17C • IL21 • IL22 • TSLP • VCAM1 • IL16","pipe":"","alterations":" ","tags":["IL6 • FLT1 • IL2 • IL10 • VEGFC • FGF • IL17A • IL23A • IL17C • IL21 • IL22 • TSLP • VCAM1 • IL16"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 06/27/2019","start_date":" 06/27/2019","primary_txt":" Primary completion: 10/27/2022","primary_completion_date":" 10/27/2022","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2022-12-20"},{"id":"b0eb940c-240b-420a-b995-ea0878dc07ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT04540224","created_at":"2021-01-18T21:43:28.301Z","updated_at":"2024-07-02T16:36:05.814Z","phase":"","brief_title":"The Relationship Between the Differences in Blood Cytokine Values in Breast Cancers.","source_id_and_acronym":"NCT04540224","lead_sponsor":"Istanbul Training and Research Hospital","biomarkers":" IL6 • CXCL8 • IL10 • IL18 • IL17A • IL23A • IL33","pipe":"","alterations":" ","tags":["IL6 • CXCL8 • IL10 • IL18 • IL17A • IL23A • IL33"],"overall_status":"Completed","enrollment":" Enrollment 78","initiation":"Initiation: 08/01/2020","start_date":" 08/01/2020","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 05/01/2022","study_completion_date":" 05/01/2022","last_update_posted":"2022-08-09"},{"id":"25fe0366-9fcc-46e6-9e6e-7ecaf7006bd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03683147","created_at":"2022-07-25T23:00:13.654Z","updated_at":"2024-07-02T16:36:06.832Z","phase":"","brief_title":"Mindfulness-Based Stress Reduction in Helping Participants With Metastatic Breast Cancer","source_id_and_acronym":"NCT03683147","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IL6 • TNFA • IL2 • CCL20 • IL10 • IL17A • IL23A • IL1RN • IL21 • IL22 • IFNL2 • IL33","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL2 • CCL20 • IL10 • IL17A • IL23A • IL1RN • IL21 • IL22 • IFNL2 • IL33"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 12/13/2017","start_date":" 12/13/2017","primary_txt":" Primary completion: 06/19/2019","primary_completion_date":" 06/19/2019","study_txt":" Completion: 04/06/2020","study_completion_date":" 04/06/2020","last_update_posted":"2022-07-25"},{"id":"d5f16fca-a36a-46b1-8c00-c70acf825591","acronym":"PRIMUS","url":"https://clinicaltrials.gov/study/NCT04247217","created_at":"2021-01-18T20:38:37.828Z","updated_at":"2024-07-02T16:36:09.862Z","phase":"","brief_title":"Immune Profiling After HDR in Local Relapsed Prostate Cancer","source_id_and_acronym":"NCT04247217 - PRIMUS","lead_sponsor":"Maastricht Radiation Oncology","biomarkers":" CXCL12 • IL23A","pipe":" | ","alterations":" CXCL12 expression","tags":["CXCL12 • IL23A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CXCL12 expression"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 02/19/2020","start_date":" 02/19/2020","primary_txt":" Primary completion: 12/23/2021","primary_completion_date":" 12/23/2021","study_txt":" Completion: 12/23/2021","study_completion_date":" 12/23/2021","last_update_posted":"2022-05-26"},{"id":"5a88e172-f3f1-4d49-981a-f074496e0ad9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05122338","created_at":"2021-11-16T12:53:42.048Z","updated_at":"2024-07-02T16:36:20.673Z","phase":"","brief_title":"Effect of Transversus Abdominis Plane Block With Compound Lidocaine and Esketamine on Pain After Surgery","source_id_and_acronym":"NCT05122338","lead_sponsor":"Tianjin Medical University General Hospital","biomarkers":" CCL2 • IL18 • IL17A • IL23A • CXCL1","pipe":"","alterations":" ","tags":["CCL2 • IL18 • IL17A • IL23A • CXCL1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 05/15/2022","primary_completion_date":" 05/15/2022","study_txt":" Completion: 06/15/2022","study_completion_date":" 06/15/2022","last_update_posted":"2021-11-16"},{"id":"4cdca706-931e-4c68-8e1f-a028059fe810","acronym":"","url":"https://clinicaltrials.gov/study/NCT00631852","created_at":"2021-01-18T02:21:00.868Z","updated_at":"2024-07-02T16:36:20.839Z","phase":"Phase 2","brief_title":"A Phase II Biomarker Trial of Gelatin Encapsulated Extract of American Ginseng Root (LEAG) in Breast Cancer","source_id_and_acronym":"NCT00631852","lead_sponsor":"Southern Illinois University","biomarkers":" IL6 • HGF • TNFA • CXCL8 • IL2 • IL10 • TGFB1 • IL23A • IL1B • IL1R1 • IL4 • LEP","pipe":"","alterations":" ","tags":["IL6 • HGF • TNFA • CXCL8 • IL2 • IL10 • TGFB1 • IL23A • IL1B • IL1R1 • IL4 • LEP"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 02/01/2008","start_date":" 02/01/2008","primary_txt":" Primary completion: 06/30/2019","primary_completion_date":" 06/30/2019","study_txt":" Completion: 06/30/2019","study_completion_date":" 06/30/2019","last_update_posted":"2021-11-11"},{"id":"44b23d2a-b087-4118-a03c-973d0274971d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03753399","created_at":"2021-01-18T18:27:13.189Z","updated_at":"2024-07-02T16:36:29.974Z","phase":"","brief_title":"Effect of Acupuncture for QoL in Gastric Cancer Patients Undergoing Adjuvant Chemotherapy: a Pilot Study","source_id_and_acronym":"NCT03753399","lead_sponsor":"Guangzhou University of Traditional Chinese Medicine","biomarkers":" CD8 • IFNG • IL6 • TNFA • CXCL12 • IL2 • IL10 • CCL4 • FGF • IL18 • IL17A • IL23A • IFNA1 • IL1B • IL21 • IL22 • BDNF","pipe":"","alterations":" ","tags":["CD8 • IFNG • IL6 • TNFA • CXCL12 • IL2 • IL10 • CCL4 • FGF • IL18 • IL17A • IL23A • IFNA1 • IL1B • IL21 • IL22 • BDNF"],"overall_status":"Completed","enrollment":" Enrollment 66","initiation":"Initiation: 01/04/2019","start_date":" 01/04/2019","primary_txt":" Primary completion: 04/27/2020","primary_completion_date":" 04/27/2020","study_txt":" Completion: 04/27/2020","study_completion_date":" 04/27/2020","last_update_posted":"2021-05-20"},{"id":"fd600316-c7bb-418b-8a8d-60f2f2263461","acronym":"","url":"https://clinicaltrials.gov/study/NCT02065297","created_at":"2021-01-18T09:30:44.438Z","updated_at":"2024-07-02T16:36:59.905Z","phase":"","brief_title":"Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)","source_id_and_acronym":"NCT02065297","lead_sponsor":"Centre Hospitalier Universitaire Dijon","biomarkers":" IL17A • IL23A","pipe":"","alterations":" ","tags":["IL17A • IL23A"],"overall_status":"Completed","enrollment":" Enrollment 143","initiation":"Initiation: 07/28/2009","start_date":" 07/28/2009","primary_txt":" Primary completion: 01/07/2016","primary_completion_date":" 01/07/2016","study_txt":"","study_completion_date":"","last_update_posted":"2019-05-06"},{"id":"52bb5c5d-556a-45d3-8898-dea38d69712f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02363491","created_at":"2021-01-18T11:15:06.236Z","updated_at":"2024-07-02T16:37:03.441Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT02363491","lead_sponsor":"Opsona Therapeutics Ltd.","biomarkers":" IFNG • IL6 • TNFA • IL10 • IL18 • IL23A • IL1B","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL10 • IL18 • IL23A • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tomaralimab (NM-101)"],"overall_status":"Completed","enrollment":" Enrollment 96","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2019-01-28"},{"id":"08338ec0-6078-48e0-bc33-7c4d40eba740","acronym":"MEL58","url":"https://clinicaltrials.gov/study/NCT01585350","created_at":"2021-01-18T06:45:23.070Z","updated_at":"2024-07-02T16:37:29.831Z","phase":"Phase 1","brief_title":"A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients","source_id_and_acronym":"NCT01585350 - MEL58","lead_sponsor":"Craig L Slingluff, Jr","biomarkers":" MYD88 • CD8 • IFNG • TNFA • CXCL12 • CXCL9 • CD4 • CD69 • IL2 • CXCL13 • IL10 • CCL19 • FOXP3 • IL17A • IL23A • CCL21 • GATA3 • IL4 • IL5","pipe":"","alterations":" ","tags":["MYD88 • CD8 • IFNG • TNFA • CXCL12 • CXCL9 • CD4 • CD69 • IL2 • CXCL13 • IL10 • CCL19 • FOXP3 • IL17A • IL23A • CCL21 • GATA3 • IL4 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 07/01/2014","primary_completion_date":" 07/01/2014","study_txt":" Completion: 10/01/2014","study_completion_date":" 10/01/2014","last_update_posted":"2016-08-12"}]